Future Self Podcast | Tips For Living A Life That Will Make Your Future Self Proud | Learn How To Podcast

http://robertingalls.com/17-blake-anderson/ (Link to the Blog Post) The Epipen is back in the news, but for all the wrong reasons. This week, only a few short months since the consumer and congressional outrage over a 500% price increase on Mylan's EpiPen, Pharmaceutical company Kaleo released their answer to the anti-allergy giant in the form of Auvi-Q. Touted as an affordable alternative, the product was originally released in 2013 with a similar price tag to the EpiPen. However, the drug was later recalled due to manufacturing problems. This time Auvi-Q hit the market with a price tag of $4,500.00, seven times the current price of the EpiPen. Kaleo has assured consumers that the high price tag is part of a complex effort to subsidize a program aimed at making the drug affordable for everyone. However, while Kaleo executive Spencer Williamson says he is encouraged by the number of insurance plans that he believes are going to cover Auvi-Q, others in the industry are not so optimistic. Adam Fein, president